Fennec Pharmaceuticals (FENC) Q2 2026 earnings — TrendMatrix coverage
IN LINEEPS — vs $0.02 est
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
Key numbers
- Reported EPS
- —
- Estimate
- $0.02
- Surprise
- —
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Around the report
Coverage in the report window
- B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18 — benzinga, 2026-08-12
- Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16 — benzinga, 2026-08-12
- Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate — benzinga, 2026-08-11